Equities Analysts Offer Predictions for CRSP Q3 Earnings

Key Points

• Brookline Capital Markets slightly raised its Q3 2026 EPS estimate for CRISPR Therapeutics to a loss of $1.30 per share from $1.31, while forecasting losses of $5.63 per share for FY2026 and $4.51 for FY2027.
• Analyst sentiment remains broadly favorable, with CRSP carrying a “Moderate Buy” consensus rating and an average price target of $68.82, despite one Sell and six Hold ratings.
• CRISPR Therapeutics recently reported $10.18 million in quarterly revenue and a $0.94-per-share loss; the stock opened at $52.45 and remains pressured by significant net losses, although CASGEVY sales and pipeline progress support the longer-term outlook.

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Research analysts at Brookline Capital Markets lifted their Q3 2026 EPS estimates for shares of CRISPR Therapeutics in a report released on Tuesday, August 4th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings of ($1.30) per share for the quarter, up from their prior forecast of ($1.31). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($4.90) per share. Brookline Capital Markets also issued estimates for CRISPR Therapeutics' Q4 2026 earnings at ($1.87) EPS, FY2026 earnings at ($5.63) EPS and FY2027 earnings at ($4.51) EPS.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its earnings results on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The firm had revenue of $10.18 million during the quarter.

Other equities research analysts have also issued research reports about the stock. Sanford C. Bernstein increased their price objective on shares of CRISPR Therapeutics from $50.00 to $56.00 and gave the company a "market perform" rating in a research note on Wednesday, May 13th. HC Wainwright restated a "buy" rating and issued a $80.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, July 8th. Evercore reaffirmed an "outperform" rating and issued a $76.00 target price on shares of CRISPR Therapeutics in a report on Monday, May 11th. UBS Group set a $80.00 price target on CRISPR Therapeutics in a research report on Friday, June 12th. Finally, Citizens Jmp reiterated a "market outperform" rating and set a $80.00 price target on shares of CRISPR Therapeutics in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $68.82.

CRISPR Therapeutics Stock Down 1.2%

CRISPR Therapeutics stock opened at $52.45 on Thursday. CRISPR Therapeutics has a fifty-two week low of $44.12 and a fifty-two week high of $78.48. The stock has a market cap of $5.07 billion, a PE ratio of -11.02 and a beta of 1.74. The firm's 50-day simple moving average is $52.52 and its 200 day simple moving average is $52.31. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.96 and a current ratio of 17.85.

Insiders Place Their Bets

In other news, insider Naimish Patel sold 3,786 shares of the stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $55.62, for a total transaction of $210,577.32. Following the completion of the transaction, the insider directly owned 19,357 shares of the company's stock, valued at $1,076,636.34. This represents a 16.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Hedge funds have recently modified their holdings of the stock. Royal Bank of Canada increased its position in CRISPR Therapeutics by 28.2% in the first quarter. Royal Bank of Canada now owns 142,696 shares of the company's stock worth $4,856,000 after buying an additional 31,392 shares during the last quarter. AQR Capital Management LLC purchased a new position in shares of CRISPR Therapeutics during the 1st quarter valued at $861,000. Woodline Partners LP grew its stake in shares of CRISPR Therapeutics by 34.3% during the 1st quarter. Woodline Partners LP now owns 136,483 shares of the company's stock worth $4,645,000 after acquiring an additional 34,883 shares during the period. Prudential Financial Inc. bought a new position in shares of CRISPR Therapeutics during the 2nd quarter worth $237,000. Finally, Invesco Ltd. increased its holdings in CRISPR Therapeutics by 138.4% in the 2nd quarter. Invesco Ltd. now owns 66,648 shares of the company's stock worth $3,242,000 after acquiring an additional 38,691 shares during the last quarter. Institutional investors own 69.20% of the company's stock.

Key Stories Impacting CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: CRISPR Therapeutics reported second-quarter revenue above expectations and a narrower-than-expected loss, helped by growing CASGEVY sales across international markets and continued progress in clinical programs. CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates
• Positive Sentiment: Piper Sandler reaffirmed its Buy rating, indicating continued confidence in CRSP’s commercial opportunity and gene-editing pipeline. Piper Sandler Reaffirms Their Buy Rating on Crispr Therapeutics AG
• Positive Sentiment: An investor analysis characterized CRSP as a “Strong Buy,” citing CASGEVY sales growth and the potential of the in-vivo editing program CTX310. CRISPR: Strong Buy CASGEVY Sales Growth and In Vivo Expansion With CTX310
• Neutral Sentiment: RBC described the second quarter as relatively quiet, with CASGEVY advancing commercially while investors await additional siRNA and pipeline data readouts. Crispr Therapeutics Posts Quiet Quarter as Casgevy Advances
• Negative Sentiment: Brookline Capital Markets lowered its Q4 2026 EPS estimate to a loss of $1.87 from $1.69 and reduced its FY2026 estimate to a loss of $5.63 from $5.36. The revisions reinforce expectations for substantial near-term losses.
• Negative Sentiment: Brookline also modestly cut its profitable long-range forecasts for FY2028, FY2029 and FY2030, although it raised its FY2027 estimate to a loss of $4.51 from $5.05. The overall changes suggest a slightly more cautious view of CRSP’s earnings ramp.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source